title: Lipoproteins and diuretics in type II diabetes.
abstract: This double-blind cross-over study was performed to investigate whether the lipoproteins in plasma were different on furosemide (Lasix Retard) and thiazide (hydrochlorthiazide) treatment in patients suffering from type II diabetes. Twenty-four patients were randomly allocated to either furosemide-hydrochlorthiazide (LR-HCT) or HCT-LR treatment. The treatment period was 12 months: 6 months on each sequence. After inclusion, the patients were seen every second month. Laboratory data were recorded at each visit. The only significant treatment effect was observed for high-density-lipoprotein3 cholesterol concentration (HDL3 cholesterol concentration), which was higher when patients were on furosemide therapy (p less than 0.05). We conclude from the present study that blood-glucose HbA1c, and the concentration of lipoproteins connected to development of atherosclerosis is unaffected whether type II diabetes patients are treated with HCT or furosemide.
authors.affiliation: Second University Clinic of Internal Medicine, University of Aarhus, Denmark.
authors.forename: A
authors.initials: A
authors.lastname: Møller
authors.forename: A
authors.initials: A
authors.lastname: Schmitz
authors.forename: M M
authors.initials: MM
authors.lastname: Pedersen
authors.forename: J S
authors.initials: JS
authors.lastname: Christiansen
mesh_terms: D000368:Aged; D001581:Benzothiadiazines; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D004232:Diuretics / Q000009:adverse effects* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005665:Furosemide / Q000009:adverse effects / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood / Q000627:therapeutic use; D011446:Prospective Studies; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001581:Benzothiadiazines; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004232:Diuretics; D008074:Lipoproteins; D049993:Sodium Chloride Symporter Inhibitors; D005665:Furosemide; D011188:Potassium